e8vk
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2004

United Therapeutics Corporation


(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-26301   52-1984749

 
 
 
 
 
(State or Other
Jurisdiction of
Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification Number)
     
1110 Spring Street
Silver Spring, MD
 
20910

 
 
 
(Address of Principal Executive Offices)
  (Zip Code)

Registrant’s telephone number, including area code:

(301) 608-9292


 


 

Item 5. Other Events.

     On March 15, 2004, United Therapeutics Corporation issued a press release announcing that its Chief Financial Officer Fred Hadeed and its General Counsel Paul Mahon have each adopted pre-arranged stock trading plans under Securities and Exchange Commission Rule10b5-1 to sell a portion of their company stock over three years as part of their individual long-term strategy for asset diversification and liquidity. In addition, Bina Aspen Rothblatt, the spouse of Chief Executive Officer Martine Rothblatt, has also adopted a three-year Rule 10b5-1 stock trading plan.

Item 7. Exhibits

     (c) Exhibits

     
Exhibit No.
  Description of Exhibit
 
   
99
  Press release dated March 15, 2004

 


 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                 
    UNITED THERAPEUTICS CORPORATION    
Dated: March 15, 2004       By:
 
Name:
Title:
  /s/ Paul A. Mahon

Paul A. Mahon
General Counsel
   

 


 

EXHIBIT INDEX

     
Exhibit No.
  Description of Exhibit
 
   
99
  Press release dated March 15, 2004